RI Dx Inc. has entered into the NASA Non-exclusive Startup License Agreement with The National Aeronautics and Space Administration No. 1263 of July 1, 2019, concerning licensing of "Biochemical Sensors Using Carbon Nanotube Arrays" (U.S. Patent No. 7,939,734).

The licensed technology demonstrates excellent performance characteristics in multiplexed quantitative measurements of different substances in fluidic media including human physiological liquids like whole blood.

RI Dx Inc. is a startup medical diagnostic company with the goal of development of innovative Handheld Point-of-Care Testing System for different medical applications with the main focus on emergency medicine.

The premier product for the devised system is the simultaneous quantitative measurement of two human blood biomarkers which detection allows to rapidly rule-out Acute Myocardial Infarction. Rapid rule-out of AMI is critically needed function in emergency departments, cardiac observation units, ambulances, and remote setting to decrease overcrowding and associated costs as well as to start urgent treatment.